211 related articles for article (PubMed ID: 12096017)
1. In vitro activity of three new triazoles and one echinocandin against Candida bloodstream isolates from cancer patients.
Laverdiere M; Hoban D; Restieri C; Habel F
J Antimicrob Chemother; 2002 Jul; 50(1):119-23. PubMed ID: 12096017
[TBL] [Abstract][Full Text] [Related]
2. National surveillance of species distribution in blood isolates of Candida species in Japan and their susceptibility to six antifungal agents including voriconazole and micafungin.
Takakura S; Fujihara N; Saito T; Kudo T; Iinuma Y; Ichiyama S
J Antimicrob Chemother; 2004 Feb; 53(2):283-9. PubMed ID: 14688039
[TBL] [Abstract][Full Text] [Related]
3. Antifungal susceptibilities of the species of the Pseudallescheria boydii complex.
Gilgado F; Serena C; Cano J; Gené J; Guarro J
Antimicrob Agents Chemother; 2006 Dec; 50(12):4211-3. PubMed ID: 17015631
[TBL] [Abstract][Full Text] [Related]
4. In vitro susceptibilities of Candida dubliniensis isolates tested against the new triazole and echinocandin antifungal agents.
Pfaller MA; Messer SA; Gee S; Joly S; Pujol C; Sullivan DJ; Coleman DC; Soll DR
J Clin Microbiol; 1999 Mar; 37(3):870-2. PubMed ID: 9986880
[TBL] [Abstract][Full Text] [Related]
5. In vitro antifungal activities of anidulafungin and micafungin, licensed agents and the investigational triazole posaconazole as determined by NCCLS methods for 12,052 fungal isolates: review of the literature.
Espinel-Ingroff A
Rev Iberoam Micol; 2003 Dec; 20(4):121-36. PubMed ID: 15456349
[TBL] [Abstract][Full Text] [Related]
6. In vitro pharmacodynamic characteristics of amphotericin B, caspofungin, fluconazole, and voriconazole against bloodstream isolates of infrequent Candida species from patients with hematologic malignancies.
Di Bonaventura G; Spedicato I; Picciani C; D'Antonio D; Piccolomini R
Antimicrob Agents Chemother; 2004 Nov; 48(11):4453-6. PubMed ID: 15504881
[TBL] [Abstract][Full Text] [Related]
7. In vitro antifungal combination effects of micafungin with fluconazole, voriconazole, amphotericin B, and flucytosine against clinical isolates of Candida species.
Nishi I; Sunada A; Toyokawa M; Asari S; Iwatani Y
J Infect Chemother; 2009 Feb; 15(1):1-5. PubMed ID: 19280292
[TBL] [Abstract][Full Text] [Related]
8. Activities of micafungin against 315 invasive clinical isolates of fluconazole-resistant Candida spp.
Messer SA; Diekema DJ; Boyken L; Tendolkar S; Hollis RJ; Pfaller MA
J Clin Microbiol; 2006 Feb; 44(2):324-6. PubMed ID: 16455878
[TBL] [Abstract][Full Text] [Related]
9. In-vitro activity of voriconazole (UK-109,496), LY303366 and other antifungal agents against oral Candida spp. isolates from HIV-infected patients.
Chávez M; Bernal S; Valverde A; Gutierrez MJ; Quindós G; Mazuelos EM
J Antimicrob Chemother; 1999 Nov; 44(5):697-700. PubMed ID: 10552989
[TBL] [Abstract][Full Text] [Related]
10. Effect of voriconazole combined with micafungin against Candida, Aspergillus, and Scedosporium spp. and Fusarium solani.
Heyn K; Tredup A; Salvenmoser S; Müller FM
Antimicrob Agents Chemother; 2005 Dec; 49(12):5157-9. PubMed ID: 16304192
[TBL] [Abstract][Full Text] [Related]
11. In vitro activities of ravuconazole and voriconazole compared with those of four approved systemic antifungal agents against 6,970 clinical isolates of Candida spp.
Pfaller MA; Messer SA; Hollis RJ; Jones RN; Diekema DJ
Antimicrob Agents Chemother; 2002 Jun; 46(6):1723-7. PubMed ID: 12019081
[TBL] [Abstract][Full Text] [Related]
12. The efficiency of the benzothiazole APB, the echinocandin micafungin, and amphotericin B in fluconazole-resistant Candida albicans and Candida dubliniensis.
Melkusová S; Bujdáková H; Volleková A; Myoken Y; Mikami Y
Pharmazie; 2004 Jul; 59(7):573-4. PubMed ID: 15296100
[TBL] [Abstract][Full Text] [Related]
13. Effect of the growth medium on the in vitro antifungal activity of micafungin (FK-463) against clinical isolates of Candida dubliniensis.
Müller FM; Kurzai O; Hacker J; Frosch M; Mühlschlegel F
J Antimicrob Chemother; 2001 Nov; 48(5):713-5. PubMed ID: 11679561
[TBL] [Abstract][Full Text] [Related]
14. In vitro interactions of micafungin with other antifungal drugs against clinical isolates of four species of Cryptococcus.
Serena C; Fernández-Torres B; Pastor FJ; Trilles L; Lazéra Mdos S; Nolard N; Guarro J
Antimicrob Agents Chemother; 2005 Jul; 49(7):2994-6. PubMed ID: 15980382
[TBL] [Abstract][Full Text] [Related]
15. In vitro susceptibilities of invasive isolates of Candida species: rapid increase in rates of fluconazole susceptible-dose dependent Candida glabrata isolates.
Ruan SY; Chu CC; Hsueh PR
Antimicrob Agents Chemother; 2008 Aug; 52(8):2919-22. PubMed ID: 18458136
[TBL] [Abstract][Full Text] [Related]
16. Antifungal susceptibility to amphotericin B, fluconazole, voriconazole, and flucytosine in Candida bloodstream isolates from 15 tertiary hospitals in Korea.
Jung SI; Shin JH; Choi HJ; Ju MY; Kim SH; Lee WG; Park YJ; Lee K;
Ann Lab Med; 2012 Nov; 32(6):426-8. PubMed ID: 23130342
[TBL] [Abstract][Full Text] [Related]
17. Trends in frequency and in vitro susceptibilities to antifungal agents, including voriconazole and anidulafungin, of Candida bloodstream isolates. Results from a six-year study (1996-2001).
Marco F; Danés C; Almela M; Jurado A; Mensa J; de la Bellacasa JP; Espasa M; Martínez JA; Jiménez de Anta MT
Diagn Microbiol Infect Dis; 2003 Aug; 46(4):259-64. PubMed ID: 12944017
[TBL] [Abstract][Full Text] [Related]
18. [Study on in vitro susceptibility of Candida spp. isolated from blood culture].
Grandesso S; Sapino B; Mazzuccato S; Solinas M; Bedin M; D'Angelo M; Gion M
Infez Med; 2012 Mar; 20(1):25-30. PubMed ID: 22475657
[TBL] [Abstract][Full Text] [Related]
19. Activity of a Long-Acting Echinocandin (CD101) and Seven Comparator Antifungal Agents Tested against a Global Collection of Contemporary Invasive Fungal Isolates in the SENTRY 2014 Antifungal Surveillance Program.
Pfaller MA; Messer SA; Rhomberg PR; Castanheira M
Antimicrob Agents Chemother; 2017 Mar; 61(3):. PubMed ID: 28052853
[TBL] [Abstract][Full Text] [Related]
20. In vitro susceptibilities of Candida bloodstream isolates to the new triazole antifungal agents BMS-207147, Sch 56592, and voriconazole.
Pfaller MA; Messer SA; Hollis RJ; Jones RN; Doern GV; Brandt ME; Hajjeh RA
Antimicrob Agents Chemother; 1998 Dec; 42(12):3242-4. PubMed ID: 9835520
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]